It is noteworthy that the anti‐cancer activity of MDM2‐inhibitor is mainly dependent on a functional p53, and we further confined the potential beneficial group from MDM2 inhibition to NSCLC patients carrying wild‐type TP53 and RTKs to maximize the efficacy. Here, TP53 is linked to cancer.